NO312671B1 - Substituerte benzamider, farmasöytiske preparater inneholdende disse samt anvendelsen av disse for fremstilling avlegemidler - Google Patents
Substituerte benzamider, farmasöytiske preparater inneholdende disse samt anvendelsen av disse for fremstilling avlegemidler Download PDFInfo
- Publication number
- NO312671B1 NO312671B1 NO19994626A NO994626A NO312671B1 NO 312671 B1 NO312671 B1 NO 312671B1 NO 19994626 A NO19994626 A NO 19994626A NO 994626 A NO994626 A NO 994626A NO 312671 B1 NO312671 B1 NO 312671B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- group
- substituted benzamides
- aromatic
- residue
- Prior art date
Links
- 150000003936 benzamides Chemical class 0.000 title claims description 12
- 229940054066 benzamide antipsychotics Drugs 0.000 title claims description 10
- 239000000825 pharmaceutical preparation Chemical class 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title description 4
- 239000003599 detergent Substances 0.000 title 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 239000002955 immunomodulating agent Substances 0.000 claims description 7
- 229940121354 immunomodulator Drugs 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 description 15
- 125000003118 aryl group Chemical group 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KRXOUFMTPNHYGO-UHFFFAOYSA-N 2-(morpholine-4-carbonyl)-n-[1-(morpholin-4-ylmethyl)-2,6-dioxopiperidin-3-yl]benzamide Chemical compound C=1C=CC=C(C(=O)N2CCOCC2)C=1C(=O)NC(C1=O)CCC(=O)N1CN1CCOCC1 KRXOUFMTPNHYGO-UHFFFAOYSA-N 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- AURSGBDEXQQALB-UHFFFAOYSA-N methyl 2-[(1-hydroxy-2,6-dioxopiperidin-3-yl)carbamoyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C(=O)NC1C(=O)N(O)C(=O)CC1 AURSGBDEXQQALB-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19843793A DE19843793C2 (de) | 1998-09-24 | 1998-09-24 | Substituierte Benzamide |
Publications (3)
Publication Number | Publication Date |
---|---|
NO994626D0 NO994626D0 (no) | 1999-09-23 |
NO994626L NO994626L (no) | 2000-03-27 |
NO312671B1 true NO312671B1 (no) | 2002-06-17 |
Family
ID=7882078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19994626A NO312671B1 (no) | 1998-09-24 | 1999-09-23 | Substituerte benzamider, farmasöytiske preparater inneholdende disse samt anvendelsen av disse for fremstilling avlegemidler |
Country Status (27)
Country | Link |
---|---|
US (1) | US6080742A (cs) |
EP (1) | EP0989121B1 (cs) |
JP (1) | JP2000095761A (cs) |
KR (1) | KR20000023339A (cs) |
CN (1) | CN1126741C (cs) |
AR (1) | AR021814A1 (cs) |
AT (1) | ATE309987T1 (cs) |
AU (1) | AU750919B2 (cs) |
BR (1) | BR9906070A (cs) |
CA (1) | CA2283021A1 (cs) |
CO (1) | CO5160263A1 (cs) |
CZ (1) | CZ295496B6 (cs) |
DE (2) | DE19843793C2 (cs) |
DK (1) | DK0989121T3 (cs) |
ES (1) | ES2251143T3 (cs) |
HK (1) | HK1026211A1 (cs) |
HU (1) | HUP9903216A3 (cs) |
IL (1) | IL132012A (cs) |
NO (1) | NO312671B1 (cs) |
NZ (1) | NZ337531A (cs) |
PE (1) | PE20001050A1 (cs) |
PL (1) | PL194897B1 (cs) |
RU (1) | RU2221783C2 (cs) |
SI (1) | SI0989121T1 (cs) |
SK (1) | SK283316B6 (cs) |
UY (1) | UY25712A1 (cs) |
ZA (1) | ZA996133B (cs) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
AU2001252196A1 (en) * | 2000-03-20 | 2001-10-03 | Grunenthal G.M.B.H. | Substituted benzamides |
US20050118137A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20050084478A1 (en) * | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
US20050118138A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
US20050201981A1 (en) * | 2004-03-10 | 2005-09-15 | Chih-Ping Liu | Method of optimizing treatment with interferon-tau |
US20040247565A1 (en) * | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
EP1188438A1 (en) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
WO2002068414A2 (en) * | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
WO2003037365A1 (en) * | 2001-11-01 | 2003-05-08 | The Johns Hopkins University | Methods and compositions for treating vascular leak using hepatocyte growth factor |
DE10163595A1 (de) * | 2001-12-21 | 2003-08-07 | Gruenenthal Gmbh | In 3-Position heterocyclisch substituierte Piperidin-2,6-dione |
CA2808646C (en) * | 2003-09-17 | 2016-08-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
US20080025948A1 (en) * | 2004-03-10 | 2008-01-31 | Chih-Ping Liu | Methods of Treatment Using Interferon-Tau |
US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
DE102004026703A1 (de) * | 2004-05-28 | 2005-12-29 | Grünenthal GmbH | Verfahren zur Herstellung von in 3-Position heterocyclisch substituierten Piperidin-2,6-dionen |
AU2007238785B2 (en) * | 2006-04-13 | 2013-02-07 | Agnieszka Ambrozak | Tetrahalogenated compounds useful as inhibitors of angiogenesis |
CN104016980B (zh) | 2008-04-23 | 2016-12-07 | 里格尔药品股份有限公司 | 用于治疗代谢障碍的甲酰胺化合物 |
US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
KR102316961B1 (ko) * | 2020-01-29 | 2021-10-26 | 프라비바이오 주식회사 | 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1545672B2 (de) * | 1965-05-08 | 1974-11-07 | Chemie Gruenenthal Gmbh, 5190 Stolberg | Dikarbonsäureimidderivate und Verfahren zu ihrer Herstellung |
-
1998
- 1998-09-24 DE DE19843793A patent/DE19843793C2/de not_active Expired - Fee Related
-
1999
- 1999-08-27 NZ NZ337531A patent/NZ337531A/xx not_active IP Right Cessation
- 1999-09-03 ES ES99117319T patent/ES2251143T3/es not_active Expired - Lifetime
- 1999-09-03 DK DK99117319T patent/DK0989121T3/da active
- 1999-09-03 DE DE59912795T patent/DE59912795D1/de not_active Expired - Lifetime
- 1999-09-03 EP EP99117319A patent/EP0989121B1/de not_active Expired - Lifetime
- 1999-09-03 AT AT99117319T patent/ATE309987T1/de active
- 1999-09-03 SI SI9930863T patent/SI0989121T1/sl unknown
- 1999-09-15 UY UY25712A patent/UY25712A1/es unknown
- 1999-09-17 AR ARP990104701A patent/AR021814A1/es unknown
- 1999-09-17 PE PE1999000942A patent/PE20001050A1/es not_active Application Discontinuation
- 1999-09-21 KR KR1019990040635A patent/KR20000023339A/ko not_active Application Discontinuation
- 1999-09-21 CO CO99059817A patent/CO5160263A1/es unknown
- 1999-09-22 AU AU48861/99A patent/AU750919B2/en not_active Ceased
- 1999-09-22 JP JP11269084A patent/JP2000095761A/ja not_active Withdrawn
- 1999-09-22 CA CA002283021A patent/CA2283021A1/en not_active Abandoned
- 1999-09-22 HU HU9903216A patent/HUP9903216A3/hu unknown
- 1999-09-23 IL IL13201299A patent/IL132012A/en not_active IP Right Cessation
- 1999-09-23 CZ CZ19993386A patent/CZ295496B6/cs not_active IP Right Cessation
- 1999-09-23 NO NO19994626A patent/NO312671B1/no not_active IP Right Cessation
- 1999-09-23 RU RU99120663/04A patent/RU2221783C2/ru not_active IP Right Cessation
- 1999-09-23 ZA ZA9906133A patent/ZA996133B/xx unknown
- 1999-09-23 PL PL335555A patent/PL194897B1/pl not_active IP Right Cessation
- 1999-09-23 BR BR9906070-1A patent/BR9906070A/pt not_active IP Right Cessation
- 1999-09-23 CN CN99120232A patent/CN1126741C/zh not_active Expired - Fee Related
- 1999-09-23 SK SK1308-99A patent/SK283316B6/sk not_active IP Right Cessation
- 1999-09-24 US US09/405,180 patent/US6080742A/en not_active Expired - Lifetime
-
2000
- 2000-09-01 HK HK00105496A patent/HK1026211A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO312671B1 (no) | Substituerte benzamider, farmasöytiske preparater inneholdende disse samt anvendelsen av disse for fremstilling avlegemidler | |
EP3508477B1 (en) | C5ar antagonists | |
US6656937B2 (en) | Substituted glutarimides and their use as inhibitors of IL-12 production | |
EP1876169B1 (en) | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | |
JP2005511621A (ja) | ケモカインレセプターの調節物質としての新規ピペリジン誘導体 | |
JP2004530632A (ja) | インテグリンレセプターインヒビター | |
EP1487817B1 (en) | Piperidine derivatives useful as modulators of chemokine receptor activity | |
EP1763507A2 (en) | Alpha-amino acid derivates with antiinflammatory activity | |
JP2005501869A (ja) | ケモカインレセプター活性の調節物質としての新規なピペリジニル−モルホリニル誘導体 | |
KR20160033747A (ko) | Alx 수용체 아고니스트로서의 피페라진 치환된 브릿지연결 스피로[2.4]헵탄 유도체 | |
JP3922431B2 (ja) | 可溶性ヒトcd23形成阻害剤としてのヒドロキサム酸誘導体 | |
BG105835A (bg) | Производни на бензамида и лекарствени средства, които ги съдържат | |
MXPA99008680A (en) | Benzamidas sustitui | |
Lipnicka et al. | New Amides of 5‐Acylamino‐3‐Methyl‐4‐Isothiazolecarboxylic Acid and their Immunotropic Activity | |
JP2014148491A (ja) | Tlr阻害作用を有するチアゾール誘導体 | |
EP2020409A1 (en) | New piperidinyl derivatives as modulators of chemokine receptor activity | |
US20050020581A1 (en) | Piperidine-2,6-diones heterocyclically substituted in the 3-position | |
JP2694321B2 (ja) | インターロイキン−1阻害剤 | |
GB2398780A (en) | 1,8-dihydroxyanthraquinone-6-carboxamide derivatives as inhibitors of T-cell proliferation for treatment of autoimmune or inflammatory conditions | |
MXPA06008480A (en) | Novel piperidines as chemokine modulators (ccr) | |
MXPA98007998A (en) | Acrylic prodrogas of n-hydroxymethyl talidomide with immunomodula activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |